Perrigo Company (PRGO) 190.00 $PRGO
Perrigo Set to Possibly Pullback After Yesterday's Rally of 3.81%
Comtex SmarTrend(R) - Mon Jul 27, 3:51PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $191.71 to a high of $196.90. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $192.47 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 190.00 (-3.60)
Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders
PR Newswire - Mon Jul 27, 2:58PM CDT
Mylan N.V. (NASDAQ: MYL) today announced that it will hold its extraordinary general meeting of shareholders in connection with its proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time (CET).
PRGO: 190.00 (-3.60), MYL: 55.63 (-0.74)
Will Headwinds Weigh on Glaxo's (GSK) Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 2:50PM CDT
Glaxo (GSK), which is scheduled to report its second-quarter 2015 earnings on Jul 29, had posted a negative earnings surprise of 12.73% last quarter.
PRGO: 190.00 (-3.60), PFE: 35.20 (+0.86), GSK: 41.70 (+0.10), NVS: 102.66 (+1.12)
Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 317.48 (+8.05), PRGO: 190.00 (-3.60), XOM: 82.36 (+3.10), MYL: 55.63 (-0.74), BMY: 64.44 (+0.14), AGN: 337.73 (+10.75), ISRG: 540.65 (-3.50), SBUX: 57.16 (+0.18), HCA: 92.51 (+0.48), IBM: 159.83 (+0.76), GM: 31.61 (+0.56), TEVA: 70.92 (-1.08), SPLK: 70.63 (+0.03), REGN: 558.40 (+18.37), NVS: 102.66 (+1.12)
Teva Confirms Allergan Generics Buy, Drops Mylan Bid
at Investor's Business Daily - Mon Jul 27, 8:10AM CDT
Teva Pharmaceutical (TEVA) confirmed reports Monday that it will buy Allergan's (AGN) generic drugs business for $40.5 billion and dropped its hostile takeover bid for Mylan Pharmaceuticals (MYL). Under the deal, Teva will pay $33.75 billion in cash...
AGN: 337.73 (+10.75), PRGO: 190.00 (-3.60), MYL: 55.63 (-0.74), TEVA: 70.92 (-1.08)
U.S. Stocks On Track For Weak Open As Chinese Stocks Sink
at Investor's Business Daily - Mon Jul 27, 7:59AM CDT
Stocks were on pace for a weak start Monday amid a sell-off in China and more corporate earnings reports. Nasdaq 100 futures slumped 21 points vs. fair value, and S&P 500 futures dropped 7 points. Futures on the Dow Jones industrial average lost 77...
AGN: 337.73 (+10.75), NSC: 84.92 (+2.12), PRGO: 190.00 (-3.60), BIDU: 163.82 (-33.86), MYL: 55.63 (-0.74), TEVA: 70.92 (-1.08), MPWR: 50.25 (+2.48), MHFI: 98.16 (-1.43), MSTR: 204.59 (+26.42)
Perrigo Company plc To Release Second Quarter Calendar Year 2015 Results On August 5, 2015
PR Newswire - Fri Jul 24, 7:02AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2015 on Wednesday, August 5, 2015 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer.
PRGO: 190.00 (-3.60)
Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:50PM CDT
Perrigo (PRGO) announced that it has entered into an agreement to acquire a leading German dietary supplement brand, Yokebe.
PRGO: 190.00 (-3.60), LGND: 106.24 (+3.69), AMAG: 66.43 (+1.36), GSK: 41.70 (+0.10)
Uptrend Call Working As Perrigo Stock Rises 19.8% (PRGO)
Comtex SmarTrend(R) - Thu Jul 23, 10:02AM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ RGO) on March 5th, 2015 at $159.07. In approximately 5 months, Perrigo has returned 19.77% as of today's recent price of $190.51.
PRGO: 190.00 (-3.60)
Perrigo to buy leading German dietary supplement brand Yokebe
M2 - Thu Jul 23, 4:41AM CDT
Pharmaceutical company Perrigo Company (NYSE RGO)(NYSE:TASE) reported on Wednesday the launch of an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe.
PRGO: 190.00 (-3.60)
Perrigo To Acquire Leading German Dietary Supplement Brand Yokebe
PR Newswire - Wed Jul 22, 6:11AM CDT
Perrigo Company plc ("Perrigo"
(NYSE: PRGO; TASE) today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately EUR 30 million in full year 2015 net sales. Yokebe, the second largest dietary brand (by market share) in Germany, comes in a shake/liquid form and is marketed within the 'meal replacement' category.
PRGO: 190.00 (-3.60)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 190.00 (-3.60), GILD: 112.99 (+2.45), MRK: 57.25 (+0.26), ASPX: 100.96 (unch), NVS: 102.66 (+1.12)
Shares of PRGO Up 17.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 16, 9:19AM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ RGO) on March 5th, 2015 at $159.07. In approximately 4 months, Perrigo has returned 17.59% as of today's recent price of $187.04.
PRGO: 190.00 (-3.60)
Watch for Perrigo to Potentially Pullback After Gaining 1.18% Yesterday
Comtex SmarTrend(R) - Tue Jul 14, 4:16PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $182.69 to a high of $187.40. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $185.00 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 190.00 (-3.60)
Hoover Dental Practice Unveils New, State-of-the-Art Website
Marketwired - Mon Jul 13, 6:08PM CDT
Perrigo Dental Care, which offers TMJ pain treatment, recently launched a new website with video testimonials, fresh content and easy scheduling options.
PRGO: 190.00 (-3.60)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 190.00 (-3.60), ANIP: 71.41 (+1.42), PFE: 35.20 (+0.86), MRK: 57.25 (+0.26), AZN: 32.86 (+0.15), SLXP: 172.96 (+0.15), TEVA: 70.90 (-1.10), GSK: 41.70 (+0.10)
Global Market Study on Clinical Nutrition: Infant Nutrition Segment To Witness Highest Growth by 2020
M2 - Fri Jul 10, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdkt5l/global_market) has announced the addition of the "Global Market Study on Clinical Nutrition: Infant Nutrition Segment To Witness Highest Growth by 2020" report to their offering. Increasing population of baby boomers is a major factor driving the consumption of clinical nutrition products. With increasing age, digestion abilities of the human digestive system decreases, thus makes it difficult for the body to absorb all the required nutrients from food. Loss of appetite is also a common problem among baby boomers. As a result, aging individuals do not get optimal amounts of nutrients. Hence, they resort to additional supplements for proper nourishment. Asia Pacific was the largest market for clinical nutrition in 2013, accounting for 41.5% of the global market share, followed by Europe and North America with market share of 24.4% and 22.6% respectively. From 2014 to 2020, the Asia Pacific clinical nutrition market is expected to grow at a CAGR 3.9%, owing to increasing demand from countries such as India and China. Increasing geriatric population is also expected to propel the growth of the Asia Pacific market. The market share of North America is expected to decrease to 21.3%, whereas that of Europe is expected to increase to 25.4% by 2020. The clinical nutrition market is bifurcated into product type (infant nutrition, enteral nutrition, and parenteral nutrition), type of infant nutrition (milk-based, soy-based, organic, probiotic/prebiotic, and others), and type of enteral nutrition (standard, and enteral nutrition for chronic illnesses). Infant nutrition segment holds the largest share of overall market in 2013 at USD 21.1 billion; and is expected to reach USD 27.1 billion in 2020, at a CAGR of 3.8% for the period 2014-2020. Under the infant nutrition segment, the milk-based segment (largest segment in 2013) increased by 4.2% CAGR during 2010 - 2013 to reach USD 8.1 billion in 2013. Under regional segment, the Asia Pacific clinical nutrition market (largest market in 2013) increased by 4.8% CAGR during 2010-2013 to reach USD 15.3 billion in 2013. The global clinical nutrition market is highly concentrated with four players accounting for approximately 69% of the market share. Nestl? SA led the market in 2013. Others major players operating in the global clinical nutrition market are Baxter International, Inc., Abbott Laboratories, B. Braun Melsungen AG, H. J. Heinz Company, Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, Hospira, Inc. and Perrigo Company Plc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porters Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market size and forecast by type Chapter 6 Market size and forecast by type of infant nutrition Chapter 7 Market size and forecast by type of enteral nutrition Chapter 8 Market size and forecast by geography Chapter 9 Competitive landscape Chapter 10 Company Profiles - Abbott Laboratories - B. Braun Melsungen AG - Baxter International, Inc. - Fresenius Kabi AG - Groupe Danone - H. J. Heinz Company - Hospira, Inc. - Mead Johnson Nutrition Company - Nestl? S.A. - Perrigo Company Plc For more information visit http://www.researchandmarkets.com/research/jd...bal_market
ABT: 51.02 (+0.33), PRGO: 190.00 (-3.60), MJN: 90.16 (+0.64), BAX: 38.04 (+0.34)
Perrigo Has Returned 13.4% Since SmarTrend Recommendation (PRGO)
Comtex SmarTrend(R) - Wed Jul 08, 5:30PM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ RGO) on March 5th, 2015 at $159.07. In approximately 4 months, Perrigo has returned 13.36% as of today's recent price of $180.32.
PRGO: 190.00 (-3.60)
Look for Shares of Perrigo to Potentially Rebound after Yesterday's 1.47% Sell Off
Comtex SmarTrend(R) - Tue Jul 07, 5:27PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $181.21 to a high of $185.86. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $182.44 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRGO: 190.00 (-3.60)
Perrigo Set to Possibly Pullback After Yesterday's Rally of 3.81%
Comtex SmarTrend(R) - Mon Jul 27, 3:51PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $191.71 to a high of $196.90. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $192.47 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 190.00 (-3.60)
Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders
PR Newswire - Mon Jul 27, 2:58PM CDT
Mylan N.V. (NASDAQ: MYL) today announced that it will hold its extraordinary general meeting of shareholders in connection with its proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time (CET).
PRGO: 190.00 (-3.60), MYL: 55.63 (-0.74)
Will Headwinds Weigh on Glaxo's (GSK) Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 2:50PM CDT
Glaxo (GSK), which is scheduled to report its second-quarter 2015 earnings on Jul 29, had posted a negative earnings surprise of 12.73% last quarter.
PRGO: 190.00 (-3.60), PFE: 35.20 (+0.86), GSK: 41.70 (+0.10), NVS: 102.66 (+1.12)
Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 317.48 (+8.05), PRGO: 190.00 (-3.60), XOM: 82.36 (+3.10), MYL: 55.63 (-0.74), BMY: 64.44 (+0.14), AGN: 337.73 (+10.75), ISRG: 540.65 (-3.50), SBUX: 57.16 (+0.18), HCA: 92.51 (+0.48), IBM: 159.83 (+0.76), GM: 31.61 (+0.56), TEVA: 70.92 (-1.08), SPLK: 70.63 (+0.03), REGN: 558.40 (+18.37), NVS: 102.66 (+1.12)
Teva Confirms Allergan Generics Buy, Drops Mylan Bid
at Investor's Business Daily - Mon Jul 27, 8:10AM CDT
Teva Pharmaceutical (TEVA) confirmed reports Monday that it will buy Allergan's (AGN) generic drugs business for $40.5 billion and dropped its hostile takeover bid for Mylan Pharmaceuticals (MYL). Under the deal, Teva will pay $33.75 billion in cash...
AGN: 337.73 (+10.75), PRGO: 190.00 (-3.60), MYL: 55.63 (-0.74), TEVA: 70.92 (-1.08)
U.S. Stocks On Track For Weak Open As Chinese Stocks Sink
at Investor's Business Daily - Mon Jul 27, 7:59AM CDT
Stocks were on pace for a weak start Monday amid a sell-off in China and more corporate earnings reports. Nasdaq 100 futures slumped 21 points vs. fair value, and S&P 500 futures dropped 7 points. Futures on the Dow Jones industrial average lost 77...
AGN: 337.73 (+10.75), NSC: 84.92 (+2.12), PRGO: 190.00 (-3.60), BIDU: 163.82 (-33.86), MYL: 55.63 (-0.74), TEVA: 70.92 (-1.08), MPWR: 50.25 (+2.48), MHFI: 98.16 (-1.43), MSTR: 204.59 (+26.42)
Perrigo Company plc To Release Second Quarter Calendar Year 2015 Results On August 5, 2015
PR Newswire - Fri Jul 24, 7:02AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2015 on Wednesday, August 5, 2015 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer.
PRGO: 190.00 (-3.60)
Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:50PM CDT
Perrigo (PRGO) announced that it has entered into an agreement to acquire a leading German dietary supplement brand, Yokebe.
PRGO: 190.00 (-3.60), LGND: 106.24 (+3.69), AMAG: 66.43 (+1.36), GSK: 41.70 (+0.10)
Uptrend Call Working As Perrigo Stock Rises 19.8% (PRGO)
Comtex SmarTrend(R) - Thu Jul 23, 10:02AM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ
RGO) on March 5th, 2015 at $159.07. In approximately 5 months, Perrigo has returned 19.77% as of today's recent price of $190.51. PRGO: 190.00 (-3.60)
Perrigo to buy leading German dietary supplement brand Yokebe
M2 - Thu Jul 23, 4:41AM CDT
Pharmaceutical company Perrigo Company (NYSE
RGO)(NYSE:TASE) reported on Wednesday the launch of an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. PRGO: 190.00 (-3.60)
Perrigo To Acquire Leading German Dietary Supplement Brand Yokebe
PR Newswire - Wed Jul 22, 6:11AM CDT
Perrigo Company plc ("Perrigo"
(NYSE: PRGO; TASE) today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately EUR 30 million in full year 2015 net sales. Yokebe, the second largest dietary brand (by market share) in Germany, comes in a shake/liquid form and is marketed within the 'meal replacement' category. PRGO: 190.00 (-3.60)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqtx6g/key_pharma_news) has announced the addition of the "Key Pharma News Issue" newsletter to their offering. This acquisition bolsters Gilead Sciences' burgeoning oncology pipeline and serves as a statement of intent. Gilead will make further oncology deals in 2015, with a large-scale potentially transformative acquisition by the end of 2016. Key Pharma News covers all major developments in the pharmaceutical industry, spanning key therapy areas including: Cancer, CNS, Autoimmune, Anti-Infectives, Generics and more. The fortnightly newsletter will provide you with the latest news and developments involving pharmaceutical companies worldwide. Being comprehensive and easy to read, Key Pharma News is the time-efficient way to keep up with every pharma development you need to know. Regular sections include: - Corporate Activity - The latest noteworthy acquisition, merger, divestiture and restructuring and capital expenditure news - Agreements - New deals, alliances and collaborations - Product News - The latest product filings, approvals, launches, withdrawals and litigations, worldwide - R&D - News of pipeline updates, late-stage clinical trials, and patent-related developments Your Benefits: - Track the companies that are shaping the industry - identify potential partnering opportunities, keep track of your competitors and highlight acquisition targets. - Understand the latest developments in current and upcoming treatments and research - be at the forefront of research and development - Monitor the highlights from major conferences and meetings across the world - never miss another update - Keep ahead of every important development Key Topics Covered: 1. EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015 2. OncoGenex Regains Rights To Custirsen From Teva 3. Curadev/Roche Enter Cancer Immunotherapy Deal 4. ViiV To Help GSK Weather A Tumultuous 2015 5. GSK Oncology Additions To Increase Novartis' Growth Trajectory 6. Biogen Will Continue To Gain Share Of MS Market 7. Esbriet Sales Will Reach Blockbuster Status In 2016 8. Teva Completes Acquisition Of Auspex Pharmaceuticals 9. Outcome Of Perrigo-Mylan-Teva Tussle Will Shape The Generic Industry 10. Xarelto Gains Approval For Additional Indications In China 11. Tecfidera Will Be Leading MS Drug In 2015 12. FDA Approves Ionsys For Acute Postoperative Pain 13. FDA Accepts Zinbryta BLA For MS 14. Pomalyst Meets Accelerated Approval Requirements For r/r MM 15. Lilly's Cyramza Gains Fourth FDA Approval 16. FDA Grants Opdivo Priority Review For Previously Untreated Advanced Melanoma 17. FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved 18. Oncolytic Immunotherapy Will Enter The Market In 2015 19. GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax 20. Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV 21. BMS To Retain Dominant Position In First-Line Advanced Melanoma Setting 22. Follow-Up Announcement Made On Preliminary Findings From Lurasidone Phase III Study 22. Arzerra Phase III Study Meets Primary Endpoint Of PFS In Relapsed CLL For more information visit http://www.researchandmarkets.com/research/tq...harma_news About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PRGO: 190.00 (-3.60), GILD: 112.99 (+2.45), MRK: 57.25 (+0.26), ASPX: 100.96 (unch), NVS: 102.66 (+1.12)
Shares of PRGO Up 17.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 16, 9:19AM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ
RGO) on March 5th, 2015 at $159.07. In approximately 4 months, Perrigo has returned 17.59% as of today's recent price of $187.04. PRGO: 190.00 (-3.60)
Watch for Perrigo to Potentially Pullback After Gaining 1.18% Yesterday
Comtex SmarTrend(R) - Tue Jul 14, 4:16PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $182.69 to a high of $187.40. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $185.00 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 190.00 (-3.60)
Hoover Dental Practice Unveils New, State-of-the-Art Website
Marketwired - Mon Jul 13, 6:08PM CDT
Perrigo Dental Care, which offers TMJ pain treatment, recently launched a new website with video testimonials, fresh content and easy scheduling options.
PRGO: 190.00 (-3.60)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 190.00 (-3.60), ANIP: 71.41 (+1.42), PFE: 35.20 (+0.86), MRK: 57.25 (+0.26), AZN: 32.86 (+0.15), SLXP: 172.96 (+0.15), TEVA: 70.90 (-1.10), GSK: 41.70 (+0.10)
Global Market Study on Clinical Nutrition: Infant Nutrition Segment To Witness Highest Growth by 2020
M2 - Fri Jul 10, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdkt5l/global_market) has announced the addition of the "Global Market Study on Clinical Nutrition: Infant Nutrition Segment To Witness Highest Growth by 2020" report to their offering. Increasing population of baby boomers is a major factor driving the consumption of clinical nutrition products. With increasing age, digestion abilities of the human digestive system decreases, thus makes it difficult for the body to absorb all the required nutrients from food. Loss of appetite is also a common problem among baby boomers. As a result, aging individuals do not get optimal amounts of nutrients. Hence, they resort to additional supplements for proper nourishment. Asia Pacific was the largest market for clinical nutrition in 2013, accounting for 41.5% of the global market share, followed by Europe and North America with market share of 24.4% and 22.6% respectively. From 2014 to 2020, the Asia Pacific clinical nutrition market is expected to grow at a CAGR 3.9%, owing to increasing demand from countries such as India and China. Increasing geriatric population is also expected to propel the growth of the Asia Pacific market. The market share of North America is expected to decrease to 21.3%, whereas that of Europe is expected to increase to 25.4% by 2020. The clinical nutrition market is bifurcated into product type (infant nutrition, enteral nutrition, and parenteral nutrition), type of infant nutrition (milk-based, soy-based, organic, probiotic/prebiotic, and others), and type of enteral nutrition (standard, and enteral nutrition for chronic illnesses). Infant nutrition segment holds the largest share of overall market in 2013 at USD 21.1 billion; and is expected to reach USD 27.1 billion in 2020, at a CAGR of 3.8% for the period 2014-2020. Under the infant nutrition segment, the milk-based segment (largest segment in 2013) increased by 4.2% CAGR during 2010 - 2013 to reach USD 8.1 billion in 2013. Under regional segment, the Asia Pacific clinical nutrition market (largest market in 2013) increased by 4.8% CAGR during 2010-2013 to reach USD 15.3 billion in 2013. The global clinical nutrition market is highly concentrated with four players accounting for approximately 69% of the market share. Nestl? SA led the market in 2013. Others major players operating in the global clinical nutrition market are Baxter International, Inc., Abbott Laboratories, B. Braun Melsungen AG, H. J. Heinz Company, Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, Hospira, Inc. and Perrigo Company Plc. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porters Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Market size and forecast by type Chapter 6 Market size and forecast by type of infant nutrition Chapter 7 Market size and forecast by type of enteral nutrition Chapter 8 Market size and forecast by geography Chapter 9 Competitive landscape Chapter 10 Company Profiles - Abbott Laboratories - B. Braun Melsungen AG - Baxter International, Inc. - Fresenius Kabi AG - Groupe Danone - H. J. Heinz Company - Hospira, Inc. - Mead Johnson Nutrition Company - Nestl? S.A. - Perrigo Company Plc For more information visit http://www.researchandmarkets.com/research/jd...bal_market
ABT: 51.02 (+0.33), PRGO: 190.00 (-3.60), MJN: 90.16 (+0.64), BAX: 38.04 (+0.34)
Perrigo Has Returned 13.4% Since SmarTrend Recommendation (PRGO)
Comtex SmarTrend(R) - Wed Jul 08, 5:30PM CDT
SmarTrend identified an Uptrend for Perrigo (NASDAQ
RGO) on March 5th, 2015 at $159.07. In approximately 4 months, Perrigo has returned 13.36% as of today's recent price of $180.32. PRGO: 190.00 (-3.60)
Look for Shares of Perrigo to Potentially Rebound after Yesterday's 1.47% Sell Off
Comtex SmarTrend(R) - Tue Jul 07, 5:27PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $181.21 to a high of $185.86. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $182.44 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PRGO: 190.00 (-3.60)
